NASDAQ:SRPT
Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.'s revenue grew 15.6% in fiscal 2025 to $2.2B while operating margin fell to −31.8%. Free cash flow was −$307.5M, −14.0% of revenue, and the diluted share count fell 7.2%.Summary generated from Sarepta Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 2, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$2.2B
Revenue growth+15.6%
Revenue, 5-yr CAGR+32.4%
Gross margin98.8%
Operating margin−31.8%
Net margin−32.5%
ROIC−40.5%
Return on equity−53.5%
Debt / equity0.73
Free cash flow−$307.5M
FCF margin−14.0%
Share count change−7.2%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 702 | 933 | 1,243 | 1,902 | 2,198 |
| Operating income | −460 | −536 | −268 | 218 | −700 |
| Net income | −419 | −703 | −536 | 235 | −713 |
| Free cash flow | −482 | −356 | −577 | −343 | −307 |
Recent filings
- 8-KEntry into a material agreement
Sep 23, 2026 - 4Insider transaction report
Sep 8, 2026 - 4Insider transaction report
Sep 8, 2026 - 8-KResults of operations and financial condition
Aug 5, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 5, 2026 - 8-KDirector or officer change
Jul 27, 2026 - 8-KDirector or officer change
Jun 4, 2026 - 8-KResults of operations and financial condition
May 6, 2026